🔴 Tscan Therapeutics is trading 12.9% down with no identified company-specific explanation

Tscan Therapeutics is trading $0.20, down 12.9%, with no identified company-specific announcement explaining the November 5 decline.

• The Nasdaq fell 2.54% and the S&P 500 fell 1.35%; this market weakness may add selling pressure, though no direct link to the stock’s move is confirmed.
• Biotech-sector context was positive and does not explain the decline. Tscan Therapeutics’ investor-relations page lists its September 2 reorganization as its latest press release.
• No volume information was provided.